In-Vitro Diagnostics (IVD) - Deal Debriefs

M&A in IVD is showing strong interest in molecular and precision diagnostics. High-value assets in liquid biopsy and spatial biology are driving premium valuations. 🚀

🚀 IVD M&A: Molecular Diagnostics and Precision Medicine
‍

In our last post, we discussed how traditional IVD is slowly commoditising, shifting M&A focus toward digital diagnostics, high-value molecular diagnostics, and precision medicine. This week, we analyse three notable acquisitions that highlight where industry leaders have placed their bets.

‍

📉 NanoString & Bruker – Despite bankruptcy proceedings, NanoString’s spatial biology technology drew intense bidding, with Bruker acquiring it for $393M to deepen its footprint in cancer research and drug development.

📉 PGDx & Labcorp – Labcorp’s $575M acquisition of PGDx reflects strong confidence in genomic cancer testing.

📉 TIB Molbiol & Roche – Roche’s $554M buyout of TIB Molbiol manifests its infectious disease diagnostics and molecular testing leadership.

‍

🔎 What this means for Investors & Healthcare Leaders:

Molecular diagnostics and precision oncology are driving premium valuations, with acquirers racing to secure high-impact technologies that can shape the future of diagnostics and healthcare.

‍

👉 Open or download the PDF to read the full report.

‍

‍Tech & Healthcare M&A Insights: Weekly market overviews and deal debriefs. Join the newsletter or follow our LinkedIn account.